Sunvozertinib is a targeted therapy agent indicated for specific gene mutations (e.g., EGFR exon20ins), primarily used in the treatment of non-small cell lung cancer (NSCLC). Its side effects are generally associated with the drug's mechanism of action; common reactions include diarrhea, rash, and stomatitis. In severe cases, it may trigger interstitial lung disease (ILD) or abnormal liver function. Strict adherence to physician instructions for medication and regular clinical monitoring are mandatory.
I. Common Side Effects and Management
Gastrointestinal reactions: Diarrhea (occurring in approximately 30%-50% of patients), nausea, vomiting, etc. Symptoms can be relieved by dietary adjustments, oral rehydration, or medications such as montmorillonite powder.
Cutaneous reactions: Rash (occurring in approximately 20%-40% of patients) and pruritus. Patients should maintain skin cleanliness, avoid sun exposure, and use antihistamines or topical corticosteroids if necessary.
Oral disorders: Oral ulcers or mucositis. It is recommended to use a soft-bristled toothbrush and mild mouthwash, and avoid irritating foods.
II. Severe Side Effects Requiring Vigilant Monitoring
1. Interstitial Lung Disease (ILD)
With an incidence of approximately 2%-5%, ILD is characterized by worsened cough, dyspnea, or hypoxemia. Immediate medication discontinuation and medical attention are required upon the onset of such symptoms, and corticosteroid therapy may be indicated.
2. Abnormal Liver Function
Elevated transaminases may occur in approximately 10%-20% of patients. Regular liver function monitoring is necessary, and temporary medication suspension or dosage adjustment may be required if abnormalities are detected.
3. Cardiotoxicity
QT interval prolongation may develop in a small number of patients, necessitating regular electrocardiographic (ECG) examinations.
III. Key Medication Precautions
Dosage adjustment per physician guidance
Physicians may reduce the dosage or suspend medication based on the severity of side effects.
Drug-drug interactions
Concomitant use with potent CYP3A4 inhibitors (e.g., clarithromycin) should be avoided, as this may increase the plasma concentration of sunvozertinib and elevate the risk of adverse reactions.
Special populations
Pregnant women, lactating women, and patients with hepatic or renal insufficiency require a careful risk-benefit assessment prior to treatment.
IV. Guidance for Urgent Medical Attention
Seek immediate medical care if any of the following symptoms occur:
Persistent high fever, or dehydration caused by severe diarrhea;
Dyspnea or chest pain;
Jaundice of the skin or sclera (a potential indicator of liver injury).
During treatment, regular rechecks of blood routine, liver and renal function, and chest imaging are required to ensure treatment safety. The efficacy and side effects of targeted drugs vary among individual patients. Close communication with the attending physician is essential, and no self-adjustment of the medication regimen is allowed.
